Gossamer Bio Inc (GOSS)

NASDAQ
10.260
-0.780(-7.07%)
After Hours
10.260
0.000(0.00%)
- Real-time Data
  • Volume:
    1,471,758
  • Bid/Ask:
    9.050/11.050
  • Day's Range:
    10.100 - 11.030

GOSS Overview

Prev. Close
11.04
Day's Range
10.1-11.03
Revenue
-
Open
11.03
52 wk Range
7.04-14.3
EPS
-3.26
Volume
1,471,758
Market Cap
753.53M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
522,791
P/E Ratio
-
Beta
-
1-Year Change
24.04%
Shares Outstanding
73,443,022
Next Earnings Date
Mar 25, 2022
What is your sentiment on Gossamer Bio Inc?
or
Market is currently closed. Voting is open during market hours.

  • Gossamer Bio EPS misses by $0.02
    • BySeeking Alpha-

    Gossamer Bio (GOSS): Q3 GAAP EPS of -$0.80 misses by $0.02.Cash, cash equivalents and marketable securities totaled $366 million as of September 30, 2021.Press Release

  • Gossamer Bio Q3 2021 Earnings Preview
    • BySeeking Alpha-

    Gossamer Bio (NASDAQ:GOSS) is scheduled to announce Q3 earnings results on Friday, November 5th, after market close.The consensus EPS Estimate is -$0.77 (+3.8% Y/Y) and the...

Gossamer Bio Inc Company Profile

Employees
196

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellSell
Technical IndicatorsBuyStrong SellStrong SellStrong SellBuy
SummaryNeutralStrong SellStrong SellStrong SellNeutral
  • 🚀🚀🚀🚀🚀🚀🚀 soon
    0
  • rocket 2day
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.